Eli Lilly Will Sell Zepbound Through Telehealth Company Ro
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...
Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback